Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer was recently asked about. A caller asked if the ...

Fintel reports that on December 4, 2025, BMO Capital maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...

Morgan Stanley has downgraded Regeneron Pharmaceuticals ( REGN) to equal-weight from overweight saying that the stock is fairly valued. The bank maintained its price target of $767 (~3% upside based ...

Fintel reports that on December 3, 2025, Morgan Stanley downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...